Issue navigation
Volume 117, Issue 5, May 2025
Editorials
Limiting surveillance in individuals with the Palestinian TP53 p. R181C founder variant—is it too soon to draw conclusions?
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 819–821, https://doi.org/10.1093/jnci/djaf009
Noninferiority trials in oncology: need for improvement, or a paradigm shift?
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 822–824, https://doi.org/10.1093/jnci/djaf004
On the road to new drugs in clinical oncology: benefit of phase 2 trials
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 825–826, https://doi.org/10.1093/jnci/djaf023
Commentaries
Enhancing capacity for primary care research in cancer survivorship: National Cancer Institute meeting report
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 827–832, https://doi.org/10.1093/jnci/djae276
The Diverse Aspects of Uterine Serous Cancer: an NCI workshop on the status of and opportunities for advancement of research
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 833–839, https://doi.org/10.1093/jnci/djae277
Review
Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 840–867, https://doi.org/10.1093/jnci/djae294
Articles
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 868–878, https://doi.org/10.1093/jnci/djae268
Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI)
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 879–889, https://doi.org/10.1093/jnci/djae313
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 889–897, https://doi.org/10.1093/jnci/djae314
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 898–906, https://doi.org/10.1093/jnci/djae318
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 907–914, https://doi.org/10.1093/jnci/djae321
Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 915–923, https://doi.org/10.1093/jnci/djae326
Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 924–933, https://doi.org/10.1093/jnci/djae327
Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 934–947, https://doi.org/10.1093/jnci/djae329
Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 948–958, https://doi.org/10.1093/jnci/djae335
Acceptability of an organ inventory for cancer screening across gender identity and intersex status
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 959–970, https://doi.org/10.1093/jnci/djae336
Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 971–979, https://doi.org/10.1093/jnci/djae330
Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 980–988, https://doi.org/10.1093/jnci/djae338
Timing of depression in relation to risk of ovarian cancer
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 989–996, https://doi.org/10.1093/jnci/djae348
An intersectional analysis of behavioral financial hardship and healthcare utilization among lesbian, gay, bisexual, transgender, queer, plus cancer survivors
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 997–1007, https://doi.org/10.1093/jnci/djae350
Childbirth after cancer among 42 896 male adolescents and young adults: a population-based study
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1008–1017, https://doi.org/10.1093/jnci/djae347
Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1018–1026, https://doi.org/10.1093/jnci/djae349
Adolescents and young adults with germline CDH1 variants and the risk of overtreatment
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1027–1035, https://doi.org/10.1093/jnci/djaf002
Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1036–1045, https://doi.org/10.1093/jnci/djaf005
Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1046–1055, https://doi.org/10.1093/jnci/djae282
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1056–1063, https://doi.org/10.1093/jnci/djaf013
Brief Communications
Assessing the effect of the COVID-19 pandemic on 1-year cancer survival in the United States
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1064–1068, https://doi.org/10.1093/jnci/djae271
TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1069–1073, https://doi.org/10.1093/jnci/djae334
Correspondence
RE: Enhancing capacity for primary care research in cancer survivorship: National Cancer Institute Meeting Report
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1074–1075, https://doi.org/10.1093/jnci/djae346
RE: Predicting persistent opioid use, abuse, and toxicity among cancer survivors
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1076–1077, https://doi.org/10.1093/jnci/djaf019
Response to Oleribe
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1078–1079, https://doi.org/10.1093/jnci/djaf020
RE: Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1080–1081, https://doi.org/10.1093/jnci/djaf025
Response to Han and Liu
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1082–1083, https://doi.org/10.1093/jnci/djaf026
Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1084–1085, https://doi.org/10.1093/jnci/djaf037
RE: Timing of depression in relation to risk of ovarian cancer
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1086–1087, https://doi.org/10.1093/jnci/djaf043
Response to Lehrer
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1088–1089, https://doi.org/10.1093/jnci/djaf044
Stat Bite
Stat Bite: Surviving or dying from colon cancer or other causes 5 years after diagnosis, Australia 2010-2014, females
JNCI: Journal of the National Cancer Institute, Volume 117, Issue 5, May 2025, Pages 1090–1091, https://doi.org/10.1093/jnci/djaf045
